Akcea Therapeutics
E561116
Akcea Therapeutics is a biopharmaceutical company focused on developing RNA-targeted therapies for rare and serious diseases, particularly in the cardiometabolic and hereditary amyloidosis space.
Statements (31)
| Predicate | Object |
|---|---|
| instanceOf | biopharmaceutical company ⓘ |
| businessModel | development and commercialization of RNA therapeutics ⓘ |
| collaboratesWith | Ionis Pharmaceuticals NERFINISHED ⓘ |
| country |
United States of America
ⓘ
surface form:
United States
|
| focus |
RNA-targeted therapies
ⓘ
cardiometabolic diseases ⓘ hereditary amyloidosis ⓘ rare diseases ⓘ serious diseases ⓘ |
| formerStockExchangeListing | NASDAQ NERFINISHED ⓘ |
| foundedBy | Ionis Pharmaceuticals NERFINISHED ⓘ |
| hasPipeline |
RNA-targeted drugs for amyloidosis
ⓘ
RNA-targeted drugs for cardiometabolic risk reduction ⓘ RNA-targeted drugs for lipid disorders ⓘ |
| headquartersLocation |
Boston, Massachusetts
ⓘ
United States of America ⓘ
surface form:
United States
|
| industry |
biotechnology
ⓘ
pharmaceuticals ⓘ |
| parentCompany | Ionis Pharmaceuticals NERFINISHED ⓘ |
| product |
Tegsedi
NERFINISHED
ⓘ
Waylivra NERFINISHED ⓘ |
| regulatoryApproval |
Tegsedi approval for hereditary transthyretin-mediated amyloidosis
ⓘ
Waylivra approval for familial chylomicronemia syndrome ⓘ |
| specialization |
hereditary transthyretin-mediated amyloidosis
ⓘ
rare lipid disorders ⓘ |
| technologyPlatform | RNA-targeted antisense technology ⓘ |
| therapeuticArea |
cardiovascular diseases
ⓘ
metabolic diseases ⓘ neurologic manifestations of amyloidosis ⓘ |
| therapyType | antisense oligonucleotide therapies ⓘ |
| tickerSymbol | AKCA NERFINISHED ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.